ProteinQure is building the world’s leading AI platform for peptide drug design, focused on extra-cellular targets. Our lead program, PQ203 for TOP1-resistant triple-negative breast cancer—a disease with no approved treatment options—has just entered Phase I trials in the US and Canada.Our platform has been validated in collaborations with four of the top 25 pharmaceutical companies and leverages proprietary physics-based methods to explore the largest accessible chemical space, spanning full scaffold diversity and more than 3,500 non-canonical building blocks. Beyond partnerships, we are advancing internal programs that use novel peptides to enable tissue-specific payload delivery, including next-generation approaches for siRNA delivery to the CNS.